Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways

An HIV-1 vaccine continues to be a major target to halt the AIDS pandemic. The limited efficacy of the RV144 phase III clinical trial with the canarypox virus-based vector ALVAC and a gp120 protein component led to the conclusion that improved immune responses to HIV antigens are needed for a more e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez, Carmen Elena, Perdiguero, Beatriz, Sánchez-Corzo, Cristina, Sorzano, Carlos Oscar S., Esteban, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795420/
https://www.ncbi.nlm.nih.gov/pubmed/29280955
http://dx.doi.org/10.3390/v10010007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795420/
https://www.ncbi.nlm.nih.gov/pubmed/29280955
http://dx.doi.org/10.3390/v10010007

Ejemplares similares